{"id":21773,"date":"2022-03-02T11:50:57","date_gmt":"2022-03-02T09:50:57","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=21773"},"modified":"2022-03-02T11:50:57","modified_gmt":"2022-03-02T09:50:57","slug":"covid-19-pacientu-gydymui-ligoninese-bus-naudojamas-dar-vienas-vaistas","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/en\/2022\/03\/02\/covid-19-pacientu-gydymui-ligoninese-bus-naudojamas-dar-vienas-vaistas\/","title":{"rendered":"COVID-19 pacient\u0173 gydymui ligonin\u0117se bus naudojamas dar vienas vaistas"},"content":{"rendered":"<p><strong><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-21774 size-full\" src=\"https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19908_793d17bf6b5b71907c36b33f30fc6c81.jpg?resize=852%2C536&#038;ssl=1\" alt=\"\" width=\"852\" height=\"536\" srcset=\"https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19908_793d17bf6b5b71907c36b33f30fc6c81.jpg?w=852&amp;ssl=1 852w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19908_793d17bf6b5b71907c36b33f30fc6c81.jpg?resize=300%2C189&amp;ssl=1 300w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19908_793d17bf6b5b71907c36b33f30fc6c81.jpg?resize=768%2C483&amp;ssl=1 768w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19908_793d17bf6b5b71907c36b33f30fc6c81.jpg?resize=18%2C12&amp;ssl=1 18w\" sizes=\"auto, (max-width: 852px) 100vw, 852px\" \/>Lietuvos gydymo \u012fstaigas netrukus pasieks naujas vaistinis preparatas, skirtas COVID-19 liga sergantiems pacientams gydyti \u2013 \u201eXevudy\u201c (veiklioji med\u017eiaga \u2013 sotrovimabas). Dalyvaudama bendrame pirkime kartu su kitomis Europos S\u0105jungos (ES) \u0161alimis, Lietuva \u012fsigijo \u0161io vaisto kiek\u012f, kurio u\u017eteks 1008 pacient\u0173 gydymui.<\/strong><\/p>\n<p>\u012esigyti vaistai jau pasiek\u0117 Lietuv\u0105 ir netrukus bus paskirstyti pagrindin\u0117ms \u0161alies ligonin\u0117ms.<\/p>\n<p>Farmacijos kompanij\u0173 \u201eGlaxoSmithKline\u201c ir \u201eVir Biotechlogogy, Inc\u201c sukurtas vaistinis preparatas \u201eXevudy\u201c buvo u\u017eregistruotas visoje ES 2021 m. gruod\u017eio 17 d. Jis gali b\u016bti skiriamas COVID-19 liga sergantiems suaugusiesiems ir paaugliams (12 met\u0173 ir vyresniems, sveriantiems ne ma\u017eiau kaip 40 kg), kuriems nereikia taikyti papildomos deguonies terapijos ir kuriems kyla didesn\u0117 rizika susirgti sunkios formos COVID-19 liga.<\/p>\n<p>COVID-19 pacient\u0173 gydymui ligonin\u0117se taip pat yra naudojami vaistai \u201eVeklury\u201c (veiklioji med\u017eiaga \u2013 remdesiviras), \u201eRonapreve\u201c (veikli\u0173j\u0173 med\u017eiag\u0173 kasirivimabo ir imdevimabo derinys) ir \u201eRegkirona\u201c (veiklioji med\u017eiaga \u2013 regdanvimabas). Taip pat Europos Komisijos sprendimu, sergan\u010diuosius COVID-19 liga galima gydyti ,,RoActemra\u201c (veiklioji med\u017eiaga \u2013 tocilizumabas) ir ,,Kineret\u201c (veiklioji med\u017eiaga \u2013 anakinra) bei deksametazonu. \u0160ie vaistai yra tiekiami Lietuvos Respublikos rinkai.<\/p>\n<p>Lietuva taip pat dalyvauja kituose Europos Komisijos vykdomuose centralizuotuose COVID-19 ligos gydymui skirt\u0173 vaist\u0173 pirkimuose. \u201eKalb\u0117jimas vienu balsu\u201c padeda susitarti d\u0117l geresni\u0173 pirkimo s\u0105lyg\u0173 \u0161alims nar\u0117ms ir u\u017esitikrina stabil\u0173 vaist\u0173 tiekim\u0105.<\/p>\n<p>\u0160iuo metu Lietuvoje prienami vaistai nuo COVID-19 ligos gali b\u016bti naudojami tik pacient\u0173 gydymui ligonin\u0117se. Vartojimui namuose ES yra u\u017eregistruotas tik vienas vaistinis preparatas \u2013 \u201ePaxlovid\u201c, kur\u012f gamina farmacijos kompanija \u201ePfizer\u201c. Galimyb\u0117s \u012fsigyti \u0161io vaisto Lietuvoje \u0161iuo metu n\u0117ra, Europos Komisija t\u0119sia derybas su gamintoju d\u0117l \u0161io preparato pirkimo ES \u0161alims.<\/p>\n<p><a href=\"https:\/\/sam.lrv.lt\/lt\/kontaktai-ziniasklaidai\" target=\"_blank\" rel=\"noopener\"><em>SAM Spaudos tarnyba<\/em><\/a><\/p>\n<p>SAM informacija<\/p>","protected":false},"excerpt":{"rendered":"<p>Lietuvos gydymo \u012fstaigas netrukus pasieks naujas vaistinis preparatas, skirtas COVID-19 liga sergantiems pacientams gydyti \u2013 \u201eXevudy\u201c (veiklioji med\u017eiaga \u2013 sotrovimabas). Dalyvaudama bendrame pirkime kartu su kitomis Europos S\u0105jungos (ES) \u0161alimis, Lietuva \u012fsigijo \u0161io vaisto kiek\u012f, kurio u\u017eteks 1008 pacient\u0173 gydymui. \u012esigyti vaistai jau pasiek\u0117 Lietuv\u0105 ir netrukus bus paskirstyti pagrindin\u0117ms \u0161alies ligonin\u0117ms. Farmacijos kompanij\u0173 \u201eGlaxoSmithKline\u201c&hellip;<\/p>","protected":false},"author":15,"featured_media":21774,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-21773","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-5Fb","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19908_793d17bf6b5b71907c36b33f30fc6c81.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/comments?post=21773"}],"version-history":[{"count":2,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21773\/revisions"}],"predecessor-version":[{"id":21776,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21773\/revisions\/21776"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media\/21774"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media?parent=21773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/categories?post=21773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/tags?post=21773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}